Market+ (iPhone)

Market+ (Android)

US STOCKS

FUNDS

FX & CRYPTO

SH/SZ-HK

HK STOCKS

IPO Plus - IPO

To-be Listed

	Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
No Upcoming IPO

Summary

Incorporated in 2019, we are a key player in the global antibody-drug conjugate (“ADC”) landscape, dedicated to the development of innovative therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. We have self-discovered two Core Products, namely DB-1303/BNT323, a HER2 ADC candidate targeting cancers including endometrial cancer (“EC”) and breast cancer (“BC”), and DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers including small-cell lung cancer (“SCLC”), castration-resistant prostate cancer (“CRPC”), esophageal squamous cell carcinoma (“ESCC”) and head and neck squamous cell carcinoma (“HNSCC”). In addition to our Core Products, we have also self-discovered (i) five other clinical-stage ADCs (namely, DB-1310, DB-1305/BNT325, DB-1312/BG-C9074, DB-1419 and DB-2304) with potential in a broad range of indications, each ranking among the most clinically advanced globally in terms of overall or lead indication development progress, according to Frost & Sullivan; (ii) two bispecific ADCs (“BsADCs”) (DB-1418/AVZO-1418 and DB-1421) that are expected to enter into clinical stage from 2025 to 2026; and (iii) multiple other preclinical ADCs. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP, MARKET AND/OR GENERATE MEANINGFUL ECONOMIC VALUE FROM OUR PIPELINE PRODUCTS, INCLUDING CORE PRODUCTS DB-1303 AND DB-1311. ADCs have emerged as one of the most promising and fastest-growing treatment modalities, with the ability to leverage the targeting and binding abilities of antibodies to precisely deliver cytotoxic payloads to cancer or other diseased cells. We have established four globally innovative ADC technology platforms. Our topoisomerase-based DITAC platform has demonstrated a wide therapeutic window (i.e., safe and effective dosage range) which potentially translates into improved efficacy and safety in the clinical setting. Topoisomerase is an enzyme that plays an essential role in DNA replication and transcription. By targeting topoisomerase, ADCs derived from our DITAC platform can potentially treat various solid tumors by inhibiting DNA replication and inducing DNA damage in cancer cells. Our know-how and execution capabilities have further enabled us to design multiple modular platforms and engineer next-generation ADC therapeutics with unique features, including novel payloads (i.e., therapeutic agents delivered to the target area) and bispecific formats, that can potentially generate synergistic and combination effects, which may lead to significant improvement in patient outcomes. All of our clinical-stage assets had obtained investigational new drug (“IND”) approvals from both the United States Food and Drug Administration (the “FDA”) and the National Medical Products Administration of the PRC (the “NMPA”) as of the Latest Practicable Date. We have seven ongoing global multi-regional clinical trials (“MRCTs”) across 17 countries and over 230 trial sites, with over 2,000 patients enrolled (more than 50% located in the U.S., EU, Australia and other regions outside China) as of the Latest Practicable Date, including four conducted in collaboration with our strategic partners for which we are currently acting as the trial sponsor. Our innovative ADC assets have attracted leading global biopharmaceutical companies, culminating in several global partnerships to date, including with BioNTech SE (“BioNTech”), BeiGene, Ltd. (“BeiGene”), Adcendo ApS (“Adcendo”), GSK plc (“GSK”), and Avenzo Therapeutics, Inc. (“Avenzo”), with over US$6.0 billion in total deal value (of which approximately US$500 million had been received as of the Latest Practicable Date). Source: Duality Bio-B (09606) Prospectus (IPO Date : 2025/04/07)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	LAV Fund VI Opportunities, L.P. (19.51%) King Star Med LP (7.71%) ZHU Zhongyuan (7.61%) Shanghai Yingjia Enterprise Management Partnership (Limited Partnership) (7.48%)
Directors	ZHU Zhongyuan (Chairman and Chief Executive Officer and Executive Director) ZHANG Shaoren (Vice President and Executive Director) SI Wen (Executive Director) CAI Zhiyang (Non-Executive Director) YU Tao (Non-Executive Director) CHUAI Shuyin (Independent Non-Executive Director) GAO Fengyong (Independent Non-Executive Director) XIE Dong (Independent Non-Executive Director)
Company Secretary	TSANG Wing Man YUAN Jiali
Principal Bankers	Industrial And Commercial Bank of China
Solicitors	JunHe LLP CM Law Firm Jun He Law Offices Harney Westwood & Riegels Kirkland & Ellis International
Auditors	PricewaterhouseCoopers
Registered Office	40/F., Dah Sing Financial Centre, 248 Queen Road East, Wanchai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.dualitybiologics.com
Email Address
Tel No
Fax No

SITEMAP

AASTOCKS.com

Members

Forgot Password

About Us

Email: support@aastocks.com

AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.

Disclaimer

You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.